COEP News & Events

Coeptis Therapeutics Holdings announced that its registration statement on Form S-4, relating to the previously announced merger transaction with Z Squared, has been declared effective by the U.S. Securities and Exchange Commission and that it will commence mailing the definitive proxy statement/prospectus relating to the Annual/Special Meeting of the Company's stockholders to be held on January 30, 2026, in connection with the Transaction. The proxy statement/prospectus is being mailed to the Company's stockholders of record as of the close of business on January 2, 2026. Notice of the Stockholder Meeting will be mailed on or about January 7, 2026 to stockholders of record as of the Record Date. While the combined company has submitted an application to list the combined company's common stock on The Nasdaq Stock Market, approval has not yet been obtained and there can be no assurance that such listing application will be approved or that the combined company will meet the applicable listing standards. If the combined company is unable to obtain listing on a national securities exchange, the combined company's securities will continue to trade on the OTC Markets following the Transaction.

Coeptis Therapeutics announced the extinguishment of its convertible note with YA II PN. The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company's outstanding debt obligations to Yorkville.

Coeptis Therapeutics announced the filing of a registration statement on Form S-4 with the Securities and Exchange Commission related to the Company's previously announced and proposed definitive merger agreement with Z Squared. The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction. The registration statement has not yet become effective, and the information contained therein is subject to change.

SNAP Biosciences and Monarch Therapeutics announced a licensing agreement to enable the development and commercialization of SNAP Biosciences' proprietary Snap-Car NK cell therapy platform in oncology using Monarch's small molecule adaptor technology. This agreement grants SNAP Biosciences access to Monarch's novel small-molecule adaptor-based technology platform, significantly broadening the functionality of the Snap-Car universal CAR-based receptor platform. Monarch's ground-breaking small molecule approach, invented by Monarch's scientific co-founders Drs. Jason Lohmueller and Alexander Deiters, enables SNAP-CAR cells to be directed by small molecule-based adaptors, enhancing the system's precision, flexibility, and modular potential across diverse therapeutic areas. Under the terms of the agreement, Monarch will receive an upfront licensing payment and is eligible for future development milestone payments, as well as royalties on net sales.